Cooper, H.L., Healy, E., Theaker, J.M. and Friedmann, P.S.
Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab).
Clinical and Experimental Dermatology, 28, (4), . (doi:10.1046/j.1365-2230.2003.01283.x).
Full text not available from this repository.
We describe a 54-year-old man with resistant pemphigus vulgaris. Standard therapies had afforded inadequate control and have been associated with considerable side-effects. The anti-CD20 monoclonal antibody, Rituximab (MabThera, Roche), was trialled with significant benefit. We discuss its potential mechanism of action.
Actions (login required)